Entretinib is a kinase inhibitor suitable for solid tumor patients carrying specific gene fusions, such as NTRK or ROS1.

1、 Drug name

1. Common name: Entretinib

2. Product Name: Rozlytrek

2、 Indications

For the treatment of solid tumors in adults and pediatric patients over one month old, the following conditions must be met:

1. Has neurotrophic tyrosine receptor kinase (NTRK) gene fusion and no known acquired resistance mutations;

2. Confirmation of FDA approved testing methods;

3. Tumor metastasis or surgical resection may lead to serious complications;

4. Progress or unsatisfactory alternative therapy after previous treatment.

3、 Specifications and characteristics

1. Dosage form: Oral

2. Validity period: 24 months (from the date of production)

3. Storage temperature: 20 ° C-25 ° C (allows short-term storage at 15 ° C-30 ° C)

4、 Main components

Active ingredient: Enrotinib

5、 Usage and dosage

The dosage form is oral capsules, and the dosage should be determined according to the patient's age, weight, and individual condition.

6、 Medication precautions

1. Before or after meals: If there are no specific restrictions, medication can be taken orally as usual;

2. Missed dose: If missed, it should be taken as soon as possible. If it is close to the next dose, skip the missed dose and do not double the dose;

3. Vomiting: If vomiting occurs after taking medication, it is not recommended to take it again. You should wait until the next scheduled time before taking the medication.

7、 Medication for special populations

1. Pediatrics: Suitable for children over 1 month old, dosage should be adjusted according to body weight;

2. Pregnant women and breastfeeding period: Not clearly stated, it is recommended to use with caution;

3. Elderly: Unless otherwise specified, individualized assessment is required.

8、 Adverse reactions

Common adverse reactions include but are not limited to: fatigue, dizziness, constipation, weight gain, edema, etc.

9、 Contraindications

There are currently no clear contraindications.

10、 Drug interactions

Enqutinib may interact with CYP3A4 enzyme inhibitors or inducers, and caution should be exercised when used in combination. The dosage may be adjusted if necessary.

11、 Storage method

1. Stored at 20 ° C-25 ° C, short-term storage at 15 ° C-30 ° C is allowed;

2. Avoid moisture and light, keep out of reach of children.

entrectinibinformation